Compile Data Set for Download or QSAR
Report error Found 167 Enz. Inhib. hit(s) with all data for entry = 11475
TargetEgl nine homolog 1(Human)
Akebia Therapeutics

US Patent
LigandPNGBDBM618972(US20230295110, Compound 6)
Affinity DataIC50: 100nMAssay Description:Time-resolved fluorescence resonance energy transfer (TR-FRET) assay was utilized to determine the enzymatic half maximal inhibitory concentration (I...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/30/2023
Entry Details
US Patent

TargetProlyl hydroxylase EGLN2(Human)
Akebia Therapeutics

US Patent
LigandPNGBDBM618972(US20230295110, Compound 6)
Affinity DataIC50: 100nMAssay Description:Time-resolved fluorescence resonance energy transfer (TR-FRET) assay was utilized to determine the enzymatic half maximal inhibitory concentration (I...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/30/2023
Entry Details
US Patent

TargetEgl nine homolog 1(Human)
Akebia Therapeutics

US Patent
LigandPNGBDBM618973(US20230295110, Compound 7.)
Affinity DataIC50: 100nMAssay Description:Time-resolved fluorescence resonance energy transfer (TR-FRET) assay was utilized to determine the enzymatic half maximal inhibitory concentration (I...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/30/2023
Entry Details
US Patent

TargetProlyl hydroxylase EGLN2(Human)
Akebia Therapeutics

US Patent
LigandPNGBDBM618973(US20230295110, Compound 7.)
Affinity DataIC50: 100nMAssay Description:Time-resolved fluorescence resonance energy transfer (TR-FRET) assay was utilized to determine the enzymatic half maximal inhibitory concentration (I...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/30/2023
Entry Details
US Patent

TargetProlyl hydroxylase EGLN2(Human)
Akebia Therapeutics

US Patent
LigandPNGBDBM618970(US20230295110, Compound 4.)
Affinity DataIC50: 100nMAssay Description:Time-resolved fluorescence resonance energy transfer (TR-FRET) assay was utilized to determine the enzymatic half maximal inhibitory concentration (I...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/30/2023
Entry Details
US Patent

TargetEgl nine homolog 1(Human)
Akebia Therapeutics

US Patent
LigandPNGBDBM618971(US20230295110, Compound 5.)
Affinity DataIC50: 100nMAssay Description:Time-resolved fluorescence resonance energy transfer (TR-FRET) assay was utilized to determine the enzymatic half maximal inhibitory concentration (I...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/30/2023
Entry Details
US Patent

TargetProlyl hydroxylase EGLN2(Human)
Akebia Therapeutics

US Patent
LigandPNGBDBM618971(US20230295110, Compound 5.)
Affinity DataIC50: 100nMAssay Description:Time-resolved fluorescence resonance energy transfer (TR-FRET) assay was utilized to determine the enzymatic half maximal inhibitory concentration (I...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/30/2023
Entry Details
US Patent

TargetProlyl hydroxylase EGLN3(Human)
Akebia Therapeutics

US Patent
LigandPNGBDBM618971(US20230295110, Compound 5.)
Affinity DataIC50: 100nMAssay Description:Time-resolved fluorescence resonance energy transfer (TR-FRET) assay was utilized to determine the enzymatic half maximal inhibitory concentration (I...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/30/2023
Entry Details
US Patent

TargetProlyl hydroxylase EGLN2(Human)
Akebia Therapeutics

US Patent
LigandPNGBDBM618975(US20230295110, Compound 9.)
Affinity DataIC50: 100nMAssay Description:Time-resolved fluorescence resonance energy transfer (TR-FRET) assay was utilized to determine the enzymatic half maximal inhibitory concentration (I...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/30/2023
Entry Details
US Patent

TargetProlyl hydroxylase EGLN3(Human)
Akebia Therapeutics

US Patent
LigandPNGBDBM618975(US20230295110, Compound 9.)
Affinity DataIC50: 100nMAssay Description:Time-resolved fluorescence resonance energy transfer (TR-FRET) assay was utilized to determine the enzymatic half maximal inhibitory concentration (I...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/30/2023
Entry Details
US Patent

TargetEgl nine homolog 1(Human)
Akebia Therapeutics

US Patent
LigandPNGBDBM618976(US20230295110, Compound 10.)
Affinity DataIC50: 100nMAssay Description:Time-resolved fluorescence resonance energy transfer (TR-FRET) assay was utilized to determine the enzymatic half maximal inhibitory concentration (I...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/30/2023
Entry Details
US Patent

TargetProlyl hydroxylase EGLN2(Human)
Akebia Therapeutics

US Patent
LigandPNGBDBM618976(US20230295110, Compound 10.)
Affinity DataIC50: 100nMAssay Description:Time-resolved fluorescence resonance energy transfer (TR-FRET) assay was utilized to determine the enzymatic half maximal inhibitory concentration (I...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/30/2023
Entry Details
US Patent

TargetProlyl hydroxylase EGLN3(Human)
Akebia Therapeutics

US Patent
LigandPNGBDBM618973(US20230295110, Compound 7.)
Affinity DataIC50: 100nMAssay Description:Time-resolved fluorescence resonance energy transfer (TR-FRET) assay was utilized to determine the enzymatic half maximal inhibitory concentration (I...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/30/2023
Entry Details
US Patent

TargetEgl nine homolog 1(Human)
Akebia Therapeutics

US Patent
LigandPNGBDBM618974(US20230295110, Compound 8.)
Affinity DataIC50: 100nMAssay Description:Time-resolved fluorescence resonance energy transfer (TR-FRET) assay was utilized to determine the enzymatic half maximal inhibitory concentration (I...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/30/2023
Entry Details
US Patent

TargetProlyl hydroxylase EGLN2(Human)
Akebia Therapeutics

US Patent
LigandPNGBDBM618974(US20230295110, Compound 8.)
Affinity DataIC50: 100nMAssay Description:Time-resolved fluorescence resonance energy transfer (TR-FRET) assay was utilized to determine the enzymatic half maximal inhibitory concentration (I...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/30/2023
Entry Details
US Patent

TargetEgl nine homolog 1(Human)
Akebia Therapeutics

US Patent
LigandPNGBDBM618975(US20230295110, Compound 9.)
Affinity DataIC50: 100nMAssay Description:Time-resolved fluorescence resonance energy transfer (TR-FRET) assay was utilized to determine the enzymatic half maximal inhibitory concentration (I...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/30/2023
Entry Details
US Patent

TargetEgl nine homolog 1(Human)
Akebia Therapeutics

US Patent
LigandPNGBDBM618967(US20230295110, Compound 1)
Affinity DataIC50: 100nMAssay Description:Time-resolved fluorescence resonance energy transfer (TR-FRET) assay was utilized to determine the enzymatic half maximal inhibitory concentration (I...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/30/2023
Entry Details
US Patent

TargetEgl nine homolog 1(Human)
Akebia Therapeutics

US Patent
LigandPNGBDBM618969(US20230295110, Compound 3.)
Affinity DataIC50: 100nMAssay Description:Time-resolved fluorescence resonance energy transfer (TR-FRET) assay was utilized to determine the enzymatic half maximal inhibitory concentration (I...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/30/2023
Entry Details
US Patent

TargetProlyl hydroxylase EGLN2(Human)
Akebia Therapeutics

US Patent
LigandPNGBDBM618969(US20230295110, Compound 3.)
Affinity DataIC50: 100nMAssay Description:Time-resolved fluorescence resonance energy transfer (TR-FRET) assay was utilized to determine the enzymatic half maximal inhibitory concentration (I...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/30/2023
Entry Details
US Patent

TargetProlyl hydroxylase EGLN3(Human)
Akebia Therapeutics

US Patent
LigandPNGBDBM618969(US20230295110, Compound 3.)
Affinity DataIC50: 100nMAssay Description:Time-resolved fluorescence resonance energy transfer (TR-FRET) assay was utilized to determine the enzymatic half maximal inhibitory concentration (I...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/30/2023
Entry Details
US Patent

TargetEgl nine homolog 1(Human)
Akebia Therapeutics

US Patent
LigandPNGBDBM618970(US20230295110, Compound 4.)
Affinity DataIC50: 100nMAssay Description:Time-resolved fluorescence resonance energy transfer (TR-FRET) assay was utilized to determine the enzymatic half maximal inhibitory concentration (I...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/30/2023
Entry Details
US Patent

TargetProlyl hydroxylase EGLN2(Human)
Akebia Therapeutics

US Patent
LigandPNGBDBM618967(US20230295110, Compound 1)
Affinity DataIC50: 100nMAssay Description:Time-resolved fluorescence resonance energy transfer (TR-FRET) assay was utilized to determine the enzymatic half maximal inhibitory concentration (I...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/30/2023
Entry Details
US Patent

TargetEgl nine homolog 1(Human)
Akebia Therapeutics

US Patent
LigandPNGBDBM618968(US20230295110, Compound 2.)
Affinity DataIC50: 100nMAssay Description:Time-resolved fluorescence resonance energy transfer (TR-FRET) assay was utilized to determine the enzymatic half maximal inhibitory concentration (I...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/30/2023
Entry Details
US Patent

TargetProlyl hydroxylase EGLN2(Human)
Akebia Therapeutics

US Patent
LigandPNGBDBM618968(US20230295110, Compound 2.)
Affinity DataIC50: 100nMAssay Description:Time-resolved fluorescence resonance energy transfer (TR-FRET) assay was utilized to determine the enzymatic half maximal inhibitory concentration (I...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/30/2023
Entry Details
US Patent

TargetProlyl hydroxylase EGLN3(Human)
Akebia Therapeutics

US Patent
LigandPNGBDBM618968(US20230295110, Compound 2.)
Affinity DataIC50: 100nMAssay Description:Time-resolved fluorescence resonance energy transfer (TR-FRET) assay was utilized to determine the enzymatic half maximal inhibitory concentration (I...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/30/2023
Entry Details
US Patent

TargetProlyl hydroxylase EGLN3(Human)
Akebia Therapeutics

US Patent
LigandPNGBDBM618987(US20230295110, Compound 19.)
Affinity DataIC50: 100nMAssay Description:Time-resolved fluorescence resonance energy transfer (TR-FRET) assay was utilized to determine the enzymatic half maximal inhibitory concentration (I...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/30/2023
Entry Details
US Patent

TargetEgl nine homolog 1(Human)
Akebia Therapeutics

US Patent
LigandPNGBDBM618988(US20230295110, Compound 20.)
Affinity DataIC50: 100nMAssay Description:Time-resolved fluorescence resonance energy transfer (TR-FRET) assay was utilized to determine the enzymatic half maximal inhibitory concentration (I...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/30/2023
Entry Details
US Patent

TargetProlyl hydroxylase EGLN2(Human)
Akebia Therapeutics

US Patent
LigandPNGBDBM618988(US20230295110, Compound 20.)
Affinity DataIC50: 100nMAssay Description:Time-resolved fluorescence resonance energy transfer (TR-FRET) assay was utilized to determine the enzymatic half maximal inhibitory concentration (I...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/30/2023
Entry Details
US Patent

TargetProlyl hydroxylase EGLN3(Human)
Akebia Therapeutics

US Patent
LigandPNGBDBM618988(US20230295110, Compound 20.)
Affinity DataIC50: 100nMAssay Description:Time-resolved fluorescence resonance energy transfer (TR-FRET) assay was utilized to determine the enzymatic half maximal inhibitory concentration (I...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/30/2023
Entry Details
US Patent

TargetProlyl hydroxylase EGLN2(Human)
Akebia Therapeutics

US Patent
LigandPNGBDBM618986(US20230295110, Compound 18.)
Affinity DataIC50: 100nMAssay Description:Time-resolved fluorescence resonance energy transfer (TR-FRET) assay was utilized to determine the enzymatic half maximal inhibitory concentration (I...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/30/2023
Entry Details
US Patent

TargetProlyl hydroxylase EGLN3(Human)
Akebia Therapeutics

US Patent
LigandPNGBDBM618986(US20230295110, Compound 18.)
Affinity DataIC50: 100nMAssay Description:Time-resolved fluorescence resonance energy transfer (TR-FRET) assay was utilized to determine the enzymatic half maximal inhibitory concentration (I...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/30/2023
Entry Details
US Patent

TargetEgl nine homolog 1(Human)
Akebia Therapeutics

US Patent
LigandPNGBDBM618987(US20230295110, Compound 19.)
Affinity DataIC50: 100nMAssay Description:Time-resolved fluorescence resonance energy transfer (TR-FRET) assay was utilized to determine the enzymatic half maximal inhibitory concentration (I...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/30/2023
Entry Details
US Patent

TargetProlyl hydroxylase EGLN2(Human)
Akebia Therapeutics

US Patent
LigandPNGBDBM618987(US20230295110, Compound 19.)
Affinity DataIC50: 100nMAssay Description:Time-resolved fluorescence resonance energy transfer (TR-FRET) assay was utilized to determine the enzymatic half maximal inhibitory concentration (I...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/30/2023
Entry Details
US Patent

TargetProlyl hydroxylase EGLN2(Human)
Akebia Therapeutics

US Patent
LigandPNGBDBM618990(US20230295110, Compound 22.)
Affinity DataIC50: 100nMAssay Description:Time-resolved fluorescence resonance energy transfer (TR-FRET) assay was utilized to determine the enzymatic half maximal inhibitory concentration (I...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/30/2023
Entry Details
US Patent

TargetProlyl hydroxylase EGLN3(Human)
Akebia Therapeutics

US Patent
LigandPNGBDBM618990(US20230295110, Compound 22.)
Affinity DataIC50: 100nMAssay Description:Time-resolved fluorescence resonance energy transfer (TR-FRET) assay was utilized to determine the enzymatic half maximal inhibitory concentration (I...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/30/2023
Entry Details
US Patent

TargetEgl nine homolog 1(Human)
Akebia Therapeutics

US Patent
LigandPNGBDBM618989(US20230295110, Compound 21.)
Affinity DataIC50: 100nMAssay Description:Time-resolved fluorescence resonance energy transfer (TR-FRET) assay was utilized to determine the enzymatic half maximal inhibitory concentration (I...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/30/2023
Entry Details
US Patent

TargetProlyl hydroxylase EGLN2(Human)
Akebia Therapeutics

US Patent
LigandPNGBDBM618989(US20230295110, Compound 21.)
Affinity DataIC50: 100nMAssay Description:Time-resolved fluorescence resonance energy transfer (TR-FRET) assay was utilized to determine the enzymatic half maximal inhibitory concentration (I...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/30/2023
Entry Details
US Patent

TargetProlyl hydroxylase EGLN3(Human)
Akebia Therapeutics

US Patent
LigandPNGBDBM618989(US20230295110, Compound 21.)
Affinity DataIC50: 100nMAssay Description:Time-resolved fluorescence resonance energy transfer (TR-FRET) assay was utilized to determine the enzymatic half maximal inhibitory concentration (I...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/30/2023
Entry Details
US Patent

TargetEgl nine homolog 1(Human)
Akebia Therapeutics

US Patent
LigandPNGBDBM618990(US20230295110, Compound 22.)
Affinity DataIC50: 100nMAssay Description:Time-resolved fluorescence resonance energy transfer (TR-FRET) assay was utilized to determine the enzymatic half maximal inhibitory concentration (I...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/30/2023
Entry Details
US Patent

TargetProlyl hydroxylase EGLN2(Human)
Akebia Therapeutics

US Patent
LigandPNGBDBM618979(US20230295110, Compound 12.)
Affinity DataIC50: 100nMAssay Description:Time-resolved fluorescence resonance energy transfer (TR-FRET) assay was utilized to determine the enzymatic half maximal inhibitory concentration (I...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/30/2023
Entry Details
US Patent

TargetProlyl hydroxylase EGLN3(Human)
Akebia Therapeutics

US Patent
LigandPNGBDBM618976(US20230295110, Compound 10.)
Affinity DataIC50: 100nMAssay Description:Time-resolved fluorescence resonance energy transfer (TR-FRET) assay was utilized to determine the enzymatic half maximal inhibitory concentration (I...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/30/2023
Entry Details
US Patent

TargetEgl nine homolog 1(Human)
Akebia Therapeutics

US Patent
LigandPNGBDBM618977(US20230295110, Compound 11.)
Affinity DataIC50: 100nMAssay Description:Time-resolved fluorescence resonance energy transfer (TR-FRET) assay was utilized to determine the enzymatic half maximal inhibitory concentration (I...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/30/2023
Entry Details
US Patent

TargetProlyl hydroxylase EGLN2(Human)
Akebia Therapeutics

US Patent
LigandPNGBDBM618977(US20230295110, Compound 11.)
Affinity DataIC50: 100nMAssay Description:Time-resolved fluorescence resonance energy transfer (TR-FRET) assay was utilized to determine the enzymatic half maximal inhibitory concentration (I...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/30/2023
Entry Details
US Patent

TargetEgl nine homolog 1(Human)
Akebia Therapeutics

US Patent
LigandPNGBDBM618979(US20230295110, Compound 12.)
Affinity DataIC50: 100nMAssay Description:Time-resolved fluorescence resonance energy transfer (TR-FRET) assay was utilized to determine the enzymatic half maximal inhibitory concentration (I...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/30/2023
Entry Details
US Patent

TargetEgl nine homolog 1(Human)
Akebia Therapeutics

US Patent
LigandPNGBDBM618985(US20230295110, Compound 17.)
Affinity DataIC50: 100nMAssay Description:Time-resolved fluorescence resonance energy transfer (TR-FRET) assay was utilized to determine the enzymatic half maximal inhibitory concentration (I...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/30/2023
Entry Details
US Patent

TargetProlyl hydroxylase EGLN2(Human)
Akebia Therapeutics

US Patent
LigandPNGBDBM618985(US20230295110, Compound 17.)
Affinity DataIC50: 100nMAssay Description:Time-resolved fluorescence resonance energy transfer (TR-FRET) assay was utilized to determine the enzymatic half maximal inhibitory concentration (I...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/30/2023
Entry Details
US Patent

TargetEgl nine homolog 1(Human)
Akebia Therapeutics

US Patent
LigandPNGBDBM618986(US20230295110, Compound 18.)
Affinity DataIC50: 100nMAssay Description:Time-resolved fluorescence resonance energy transfer (TR-FRET) assay was utilized to determine the enzymatic half maximal inhibitory concentration (I...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/30/2023
Entry Details
US Patent

TargetProlyl hydroxylase EGLN3(Human)
Akebia Therapeutics

US Patent
LigandPNGBDBM618999(US20230295110, Compound 47. | US20230295110, Compo...)
Affinity DataIC50: 100nMAssay Description:Time-resolved fluorescence resonance energy transfer (TR-FRET) assay was utilized to determine the enzymatic half maximal inhibitory concentration (I...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/30/2023
Entry Details
US Patent

TargetEgl nine homolog 1(Human)
Akebia Therapeutics

US Patent
LigandPNGBDBM619000(US20230295110, Compound 32.)
Affinity DataIC50: 100nMAssay Description:Time-resolved fluorescence resonance energy transfer (TR-FRET) assay was utilized to determine the enzymatic half maximal inhibitory concentration (I...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/30/2023
Entry Details
US Patent

TargetProlyl hydroxylase EGLN2(Human)
Akebia Therapeutics

US Patent
LigandPNGBDBM619000(US20230295110, Compound 32.)
Affinity DataIC50: 100nMAssay Description:Time-resolved fluorescence resonance energy transfer (TR-FRET) assay was utilized to determine the enzymatic half maximal inhibitory concentration (I...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/30/2023
Entry Details
US Patent

Displayed 1 to 50 (of 167 total ) | Next | Last >>
Jump to: